medicare coverage of glp-1 drugs Bridge Program 2026: Drugs, Costs, Eligibility Some insurers are dropping GLP-1
Description
Anvari M, Paterson CA, Daniel EE, McDonald TJ
One of the largest retrospective studies to date, by Villumsen et al., 89 utilized Danish national registry data from 2007 to 2019 to assess 3751 patients with IBD (77.5% UC, 22.5% CD) and T2DM
In laboratory models, GLP-1 receptor agonists appeared to reduce neuroinflammation, improve mitochondrial activity, and decrease oxidative stress
[DOI] [PubMed] [Google Scholar] 76.Mantelmacher FD, et al
PMID: 34626851 Dungan K, DeSantis A (2016): Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus
